Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Company Overview - Royalty Pharma plc announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026, to lead the company's royalty business in Asia [1] - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with various innovators [5] Industry Insights - In 2025, the out-licensing of Chinese medicines reached over $130 billion, a significant increase from approximately $14 billion in 2021, indicating a growing recognition of innovation in Asia by multinational pharmaceutical companies [2] - The momentum in the Asia-based biotechnology sector is expected to continue into 2026 and beyond, with increasing innovation in modalities, therapeutic areas, and deal structures [2] Market Opportunities - The royalties from biotechnology transactions are creating new market opportunities for royalty-based funding, with Royalty Pharma aiming to build the royalty market in greater Asia [3] - Kenneth Sun emphasized the potential for royalty creation in Asia to provide flexible, non-dilutive capital at significant scale to innovative biotech companies [4]